Market Overview

Deutsche Bank Reiterates Buy on Vertex Pharmaceuticals Following Press Release

Share:
Related VRTX
5 Pharma & Biotech Stocks That Could Be Big Winners in Q3 Earnings
Benzinga's Bulls And Bears Of The Past Week: Netflix, Intel, Tesla And More

Following the press release issued earlier Tuesday morning by Vertex Pharmaceuticals (NASDAQ: VRTX), Deutsche Bank analyst, Robyn Karnauskas reiterated the firm's Buy rating and $103.00 price target for Vertex shares.

Karnauskas wrote, "Bottom line: We believe that this is the first step in Vertex platform treating entire cystic fibrosis population." Karnauskas based this on the belief that doctors will use the regimen for the high unmet need among the cystic fibrosis community for a viable treatment.

For a more detailed look into the press release see Why Is Vertex Pharmaceuticals Up More Than 50 Percent?

Latest Ratings for VRTX

DateFirmActionFromTo
Sep 2017DA DavidsonInitiates Coverage OnBuy
Sep 2017RBC CapitalInitiates Coverage OnOutperform
Jul 2017CitigroupMaintainsBuy

View More Analyst Ratings for VRTX
View the Latest Analyst Ratings

Posted-In: Deutsche Bank Robyn KarnauskasAnalyst Color Price Target Reiteration Analyst Ratings

 

Related Articles (VRTX)

View Comments and Join the Discussion!
Loading...

Partner Center

Loading...